Skip to Content

Bogart Wealth LLC increases its stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Bogart Wealth LLC increases its stake in Gilead Sciences, Inc. (NASDAQ:GILD)

The most recent 13F report that Bogart Wealth LLC submitted to the SEC revealed that during the third quarter of 2018, the investment firm increased the number of Gilead Sciences, Inc. (NASDAQ: GILD) shares that it owned by 14.4%. The biopharmaceutical company’s total number of shares in ownership of the company’s stock has increased to 131,126 due to the purchase of an additional 16,551 shares of the company’s stock during the period in question. As of the end of the most recent fiscal quarter, Bogart Wealth LLC had paid $8,089,000 to acquire ownership of Gilead Sciences.

Institutional investors and hedge funds have bought and sold company shares in recent transactions. These transactions involve the company’s stock. The Teacher Retirement System of Texas increased the amount of Gilead Sciences stock owned by 10.9% during the third quarter of this year. The Teacher Retirement System of Texas now has a total of 558,649 shares in the biopharmaceutical business after purchasing an additional 55,092 shares during the quarter for a total investment of 558,649. The value of these shares on the market as of right now is $34,463,000. Stone Point Wealth LLC increased the amount of Gilead Sciences stock owned by 6.8% during the third quarter. Stone Point Wealth LLC now has 23,235 shares of the biopharmaceutical company’s stock, which are currently valued at $1,434,000, after purchasing an additional 1,475 shares during the period in question. This brings the total number of shares that the company owns to a total of 23,235. Adell Harriman & Carpenter Inc. increased the proportion of Gilead Sciences stock owned by 3.3% during the third quarter. After making an additional purchase of 200 shares during the quarter, Adell Harriman & Carpenter Inc. now owns a total of 6,228 shares of the biopharmaceutical company, which has a market valuation of $384,000. This is because the company purchased during the quarter. During the third quarter, SlateStone Wealth LLC realized a 29.5% increase in the proportion of its holdings allocated to Gilead Sciences. SlateStone Wealth LLC now has a total of 8,108 shares of the biopharmaceutical company’s stock after purchasing an additional 1,847 shares during the most recent period. These shares are worth $500,000 at the current market price. In the third quarter, Global Retirement Partners LLC increased the amount of Gilead Sciences stock owned by 7.4%, making this the last and most important point. After making an additional purchase of 168 shares during the relevant period, Global Retirement Partners LLC now owns 2,437 shares of the biopharmaceutical company’s stock. Based on the current market price, this gives the company a market value of $191,000. Institutional investors and hedge funds jointly own 78.72% of the total shares outstanding in the company, making up the majority of the company’s stock ownership.

During the trading session on Thursday, the price of GILD stock increased by $0.31, bringing it to $80.05. The number of shares in the company that changed hands was 159,812, which is significantly lower than the daily volume average of 5,771,312 shares. Gilead Sciences, Inc. experienced price ranges that ranged from a low of $57.17 to a high of $89.74 over the past year. These prices represent the company’s low and high points, respectively. In the most recent 50 trading days, the company’s simple moving average was $85.82, while the average for the most recent 200 trading days was $72.48. The company has a market capitalization of $105.42 billion, a price-to-earnings ratio of 31.63, a price-to-earnings-growth ratio of 0.83, and a beta coefficient of 0.45. All of these metrics indicate that the company is relatively stable. The quick ratio comes in at 1.16 to 1, the current ratio comes in at 1.30 to 1, and the debt-to-equity ratio comes in at 1.14 to 1.

On Thursday, October 27th, Gilead Sciences, Inc. (NASDAQ: GILD) announced the release of the company’s most recent quarterly earnings report. The biopharmaceutical company reported earnings per share for the quarter of $1.90, which is $0.46 higher than the consensus estimate of $1.44 among analysts working in the industry. It can be seen that Gilead Sciences had a successful performance by looking at their net margin of 12.29% and their return on equity of 38.51%. The company’s quarterly sales came in at $7.04 billion, significantly higher than the predictions, which averaged out to be $6.12 billion. Analysts specializing in stock market research anticipate that Gilead Sciences, Inc. will generate earnings of $7.08 per share during the current fiscal year.

In addition, the business had previously announced and paid out a quarterly dividend, wh

Tags

Leave a comment

Your email address will not be published. Required fields are marked *